Physician profile
Alan Thomas
NPI 1528066313
$13,097.91
in general payments reported to CMS, 2019-2025
53 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 78% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,060 · 2020: $3,016 · 2021: $3,190 · 2022: $1,123 · 2023: $1,131 · 2024: $1,243 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,675 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,675.32 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,286.53 | 2019-2025 | Airsupra, Symbicort |
| Glaxosmithkline, LLC. | $2,395.71 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,204.23 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Electromed, INC. | $809.17 | 2019-2025 | Smartvest |
| Grifols USA, LLC | $687.38 | 2019-2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $570.57 | 2021-2025 | Inspire |
| Genentech USA, INC. | $375.27 | 2019-2022 | |
| Insmed, INC. | $358.87 | 2019-2023 | Arikayce |
| United Therapeutics Corporation | $312.61 | 2021-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $308.73 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $276.38 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $253.73 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $209.06 | 2019-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $165.19 | 2023-2025 | Watchman Flx, Enroute Transcarotid Stent, Emblem Mri S-Icd |
| Janssen Pharmaceuticals, INC | $133.59 | 2019-2024 | Xarelto |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.